Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (20614)	12/1/2006 8:42:41 AM
From: Galirayo	Respond to of 23958

That looks more like a nasty down trend. A Good Dead Cat "should" be in an Up Trend .. then in 1 or 2 days loose 30% PLUS. SCT Qualified and might be worth a another look. That original 75% haircut it got was a good play for you. It was over done even in a Down trend. The theory behind is simple .. just a reversion to the mean. stockcharts.com

To: ACAN who wrote (20614)	12/1/2006 9:06:57 AM
From: Galirayo	Read Replies (1) \| Respond to of 23958

Talk about getting Hacked. Makes me wonder what happened to this one. They must have nothing else in the pipeline. stockcharts.com AstraZeneca (nyse: AZN - news - people ) and Renovis (nasdaq: RNVS - news - people ) suffered big stock declines last week after the companies announced disappointing results for an experimental stroke drug. The developmental partners said new data for NXY-059 failed to meet both the primary and secondary goals of a late-stage trial involving more than 3,000 stroke victims. AstraZeneca, which said it will halt development of the drug, saw its stock close to a weekly loss of 10%. Shares of Renovis, a tiny biotech based in South San Francisco, fared much worse with a huge decline of 76%. Cowen & Company downgraded Renovis shares to "neutral" from "outperform" on Oct. 26. "With the rest of Renovis’s pipeline very immature, following today's sell-off we expect the stock to trade in-line with the market for the next 12 to 24 months," the firm said.